Unichem Laboratories Reports Q1 Financial Results for FY27, Showing Varied Performance Across Entities
Unichem Laboratories Limited has released its unaudited financial statements for the first quarter ended June 30, 2026. The company's Board of Directors approved these results at a meeting held on August 11, 2026. Unaudited results were provided for both the consolidated and standalone entities.Consolidated Financial Results
The unaudited consolidated financial results for the quarter ending June 30, 2026, reflect performance across various subsidiaries. The company operates in a single reportable segment, identified as 'Pharmaceuticals'.Key financial highlights from the Consolidated Unaudited Financial Statements are presented below:
| Particulars | Q1 Ended 30.06.2026 (Unaudited) | Q1 Ended 31.03.2026 (Unaudited) | Q1 Ended 30.06.2025 (Unaudited) | FY Ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 632.62 | 575.12 | 526.60 | 2,201.85 |
| Other income | 15.61 | 23.47 | 6.82 | 63.06 |
| Total income | 648.23 | 598.59 | 533.42 | 2,264.91 |
| Cost of materials consumed | 190.02 | 184.03 | 217.48 | 768.83 |
| Purchase of stock-in-trade | 67.25 | 91.81 | 51.01 | 231.51 |
| Changes in inventories of stock-in-trade, finished goods and work-in progress | 31.32 | (7.82) | (23.44) | 20.21 |
| Employee benefits expense | 103.31 | 92.85 | 107.42 | 396.63 |
| Finance costs | 6.62 | 9.39 | 6.54 | 31.59 |
| Depreciation and amortization expenses | 29.94 | 30.61 | 31.79 | 125.12 |
| Other expenses | 170.78 | 166.57 | 151.64 | 600.50 |
| Total expenses | 599.24 | 567.44 | 542.44 | 2,174.39 |
| Profit/ (Loss) before exceptional items and tax | 48.99 | 31.15 | (9.02) | 90.52 |
| Exceptional items - expenses/(income) | - | 12.36 | - | (201.86) |
| Profit/ (Loss) before tax | 48.99 | 18.79 | (9.02) | 292.38 |
| Tax expense | 7.52 | 7.88 | 1.45 | 39.54 |
| Profit/ (Loss) for the period after tax | 41.47 | 10.91 | (10.47) | 252.84 |
The consolidated results include data from subsidiaries in various countries, including Niche Generics Limited in the United Kingdom, Unichem Pharmaceuticals (USA), Inc. in the USA, Unichem SA (Pty) Limited in South Africa, and Unichem Farmaceutica Do Brasil Ltda in Brazil.
Standalone Financial Results
The standalone results for the quarter ended June 30, 2026, also showed specific performance metrics for the company entity. The financial statements were prepared according to Ind AS 34.Key figures from the Standalone Unaudited Financial Statements are as follows:
| Particulars | Q1 Ended 30.06.2026 (Unaudited) | Q1 Ended 31.03.2026 (Unaudited) | Q1 Ended 30.06.2025 (Unaudited) | FY Ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 366.27 | 356.24 | 384.25 | 1,412.29 |
| Other income | 16.72 | 22.22 | 4.25 | 62.90 |
| Total income | 382.99 | 378.46 | 388.50 | 1,475.19 |
| Cost of materials consumed | 168.80 | 149.98 | 203.88 | 671.59 |
| Purchase of stock-in-trade | 0.17 | 0.23 | 0.12 | 1.05 |
| Changes in inventories of stock-in-trade, finished goods and work-in progress | (14.53) | 12.10 | (22.08) | (7.28) |
| Employee benefits expense | 73.50 | 64.64 | 72.86 | 277.22 |
| Finance costs | 1.29 | 4.09 | 1.93 | 11.80 |
| Depreciation and amortization expenses | 28.69 | 28.97 | 29.93 | 119.03 |
| Other expenses | 117.69 | 116.80 | 103.73 | 419.35 |
| Total expenses | 375.61 | 376.81 | 390.37 | 1,492.76 |
| Profit/ (Loss) before exceptional items and tax | 7.38 | 1.65 | (1.87) | (17.57) |
| Exceptional items - expenses/(income) | - | 12.36 | - | (226.98) |
| Profit/ (Loss) before tax | 7.38 | (10.71) | (1.87) | 209.41 |
Notable Financial Details and Expense Items
In the consolidated results, a one-time increase in provision for employee benefits occurred due to the recognition of past service costs amounting to 15.40 crores during the year ended March 31, 2026. Furthermore, concerning the European Commission fine settlement received by Niche Generics Ltd., the interest component of the outstanding fine from previous years was recorded under exceptional items for the consolidated company in FY 2026.The standalone results also noted a similar item regarding employee benefits and reported a total of (226.98) crores in exceptional items across the three quarters and the financial year ended March 31, 2026. During June 2026, the company invested USO 80,000 (equivalent to approximately 0.76 crores) towards redeemable preference shares in its wholly owned subsidiary, Unichem (China) Pvt Ltd.
UNICHEMLAB Stock Price Movement
As of 2:06 PM, shares of Unichem Laboratories Limited are edging higher in live trading, gaining 0.07% or ₹0.35 and currently standing at ₹507.5. The stock remains within a narrow intraday range while over 120,222 shares have been traded today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.